Concord Biotech Q1 Results
- BSE: 543960
- NSE: CONCORDBIO
- ISIN: INE338H01029
- Sector: Biotechnology & Drugs
BSE
1,183.25
-45.75 (-3.72%)
-45.75 (-3.72%)Volume6.76 K
Updated: Fri 13 Feb, 2026 | 15:47:49
NSE
1,184.40-44.50 (-3.62%)
-44.50 (-3.62%)Volume1.09 L
Updated: Fri 13 Feb, 2026 | 15:40:25
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q1 Results Highlights
Quarter ended Jun 25
Note: Comparison is on QoQ basis
Quarterly - Concord Biotech Q1 Results
*All figures in crores except per share values
| Fiscal Period | Jun 25 | Mar 25 | QoQ Comp | Jun 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 160.37 | 254.08 | -36.88% | 147.70 | 8.58% |
| Depreciation/ Amortization | 17.78 | 14.62 | 21.62% | 13.18 | 34.89% |
| Operating Income | 43.62 | 175.81 | -75.19% | 68.10 | -35.95% |
| Net Income | 44.06 | 140.39 | -68.62% | 59.59 | -26.07% |
| Other Operating Expenses Total | 30.11 | -40.23 | 0.00% | 54.56 | -44.81% |
| Net Income Before Taxes | 58.73 | 183.54 | -68.00% | 79.52 | -26.14% |
| Total Revenue | 203.99 | 429.88 | -52.55% | 215.80 | -5.47% |
| Selling/ General/ Admin Expenses Total | 37.90 | 38.97 | -2.74% | 31.66 | 19.69% |
| Diluted Normalized EPS | 4.21 | 13.41 | -68.61% | 5.70 | -26.14% |